Ignite Creation Date:
2025-12-26 @ 12:14 PM
Ignite Modification Date:
2026-01-13 @ 5:40 PM
Study NCT ID:
NCT02423200
Status:
COMPLETED
Last Update Posted:
2018-04-03
First Post:
2015-04-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
Sponsor:
EIP Pharma Inc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-04
Start Date Type:
None
Primary Completion Date:
2016-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-11
Completion Date Type:
ACTUAL
First Submit Date:
2015-04-03
First Submit QC Date:
None
Study First Post Date:
2015-04-22
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-01-02
Results First Submit QC Date:
None
Results First Post Date:
2018-04-03
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-04-02
Last Update Post Date:
2018-04-03
Last Update Post Date Type:
ACTUAL